Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Viemed Healthcare Inc VMD

Viemed Healthcare, Inc. through its subsidiaries, is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counselling to patients in their homes using cutting edge technologies. The Company’s products and services include Home Medical Equipment, In-home sleep testing, and Healthcare staffing. Home Medical Equipment provides respiratory and other home medical equipment, including home ventilation, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) devices, percussion vests, and other medical equipment. In-home sleep testing provides in home sleep apnea testing services. Healthcare staffing provides healthcare staffing and recruitment services. The Company provides home medical equipment services through its interest in East Alabama HomeMed, LLC (HomeMed).


NDAQ:VMD - Post by User

Comment by lscfaon May 29, 2021 3:04pm
235 Views
Post# 33292863

RE:RE:RE:RE:RE:RE:RE:Bad news/ Good news

RE:RE:RE:RE:RE:RE:RE:Bad news/ Good news

Co. used to disclose what the average exercise price was but no more. Since they grant these phantom shares in June each year I guesstimated the exercise price. Looks like shares granted in 2019 and 2020 May get little to no payout on their 1/3 vested this June. The 500,000 is the 3rd vesting out of 3 for the greedy mgmt grant in 2018.

 

 

$cdn

Exercise pr

Jun 2021 price

Cash payout

100,000

13.25

10

-325,000

100,000

9.50

10

50,000

500,000

4.60

10

2,700,000

 



lscfa wrote:

it's more complicated than that. It also gets prorated by time to vesting date.....


For the Company’s phantom share units settled in cash, the Company computes the fair value of the phantom share units using the closing price of the Company's stock at the end of each period and records a liability based on the percentage of requisite service.

 

beancounter11 wrote: Yes I understand it.  It is mark to market, which basically means that the phantom share units are recorded at fair market value every Quarter.  So basically the formula would be:

Opening balance
add: units issued
Less: units expired
Less: Units vested
= ending balance

Expenses would be the change in share price multiplied by the change in th balance.  I can't calculate it exactly because we won't know the value and date of the issued and the date of the vesting.  

When they hit the vesting date, they are paid out in cash versus a stock option which needs to be exercised.

A rough calculation based on your numbers would be share price change of (7.81(today's close) -10.12= $2.31.

You would then multiply the $2.31 * o/s (roughly 761,000 using your average outstanding) this would be an expense recovery of $1,757,910.  

Now a big fluctuation could be when the vesting date is?  I am not sure if this is any of the company's filing I am not going to look for it right now.  For example if they already vested early in the Q then the expenses is already booked, if they vest today then we will see a bigger recovery.  I think this is likely a mute point because the greedy management usually just issue more phantoms when the others vest so it may not have that big of an impact.

Regardless the general thing is the phantom shares are relatively static then the share price change either gives us a big expense or a big expense recovery.  This is the reason the plan is flawed when looking at comparisions of G&A  Q vs Q because the share price change is very random.

Have a great week end everybody.
 

 

lscfa wrote:

I'm not sure about that. Anyone know how to value these damn phantom shares?
 

 

$US

Fair value liability

Expensed to SG&A

No of Shs o/s

Vested

Ending Sh pr

Jun30/20

4,699,000

4,308,000

1,042,000

601,000

9.60

Mar31/20

4,593,000

(697,000)

1,328,000

0

4.76

Dec31/19

5,290,000

 

1,350,000

0

6.20

 

 

 

 

 

 

$US

Fair value liability

Expensed to SG&A

No of Shs o/s

Vested

Ending Sh pr

Jun30/21 (e)

 

 

571,000

700,000

 

Mar31/21

7,808,000

2,465,000

951,000

0

10.12

Dec31/20

5,344,000

 

985,000

0

7.76

 

 

 

 

 

 

 


 

donmayne wrote: If the share price closes at a low at the end of Q2, will that reverse all the phantom share charges for the prior three quarters?  That would amount to .075 per share boost to quarterly income.

That phantom share plan was a bad plan poorly executed.  It has cost the company by the wild volatility that it generates in the earnings. It was so short sighted not to have abandoned that plan and replaced it with a better plan that provides an equivalent incentive.  

In any event, I expect a reversal of phantom share expenses will boost Q2s income.

 

 


 




<< Previous
Bullboard Posts
Next >>